ARDM - Aradigm Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
0.1200
-0.3400 (-73.91%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close0.4600
Open0.3125
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0701 - 0.3500
52 Week Range0.0701 - 0.3500
Volume540,972
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 2, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire

    Aradigm Announces Receipt of Final FDA Minutes for the Type B Meeting on January 25, 2019

    At the Type B meeting, Aradigm presented the results of the Third Party Evaluation (TPE) completed in December 2019 that addressed the clinical issue raised by the FDA in the complete response letter (CRL) received in January 2018. As previously announced, the TPE results confirm the primary and secondary pulmonary exacerbation (PE) endpoint analyses of the ORBIT-3 and ORBIT-4 trials as submitted in the NDA in July 2017. Based on the Orphan Drug Designation in bronchiectasis for Apulmiq, Aradigm asked the FDA to exercise its flexibility and allow a resubmission of the NDA.

  • Business Wire

    Aradigm Announces Plans for Reorganization Under Chapter 11 of the U.S. Bankruptcy Code

    Aradigm Corporation (ARDM) (“Aradigm” or the “Company”) has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the Alameda County Court District to facilitate the sale of its assets. On February 11, 2019, Aradigm determined that without confirmation of funding from their primary investor and partner, the Company would not have enough funds to meet all of their future financial obligations. As a result, Aradigm’s Board of Directors issued a unanimous consent authorizing Aradigm Corporation to file for protection under Chapter 11 of the U.S. Bankruptcy Code.

  • Business Wire

    Aradigm Announces Submission of Responses to EMA Day 120 Questions and Meeting with FDA

    As part of the EMA regulatory review calendar for marketing authorization application submissions to the EMA for approval, Aradigm will expect a Day 180 List of Outstanding Issues in late March. The clock will stop again until Aradigm responds to those issues, usually within thirty to sixty days. One month later, Aradigm could expect an opinion by the Committee for Medicinal Products for Human Use (CHMP) to our request for approval or a presentation to the CHMP during a formal hearing, which will be followed by the CHMP opinion a month later.

  • Business Wire

    Aradigm Announces Detailed Third Party Evaluation Results for Apulmiq (FDA)/Linhaliq (EMA)

    Aradigm Corporation (ARDM) ("Aradigm" or the "Company") today announced specific, detailed results of an independent third party evaluation (TPE) of the Phase 3 clinical trial results for Apulmiq. As previously reported, Aradigm received a Complete Response Letter (CRL) on 26 January 2018, from the US Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Apulmiq as a treatment for non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infection with Pseudomonas aeruginosa (P. aeruginosa). The CRL identified issues related to a manual re-review of patient-level pulmonary exacerbation (PE) data conducted by Aradigm after errors were discovered in the analyses performed by a contract research organization.

  • Business Wire

    Aradigm Announces Results of Third Party Verification for Apulmiq (formerly Linhaliq)

    Aradigm received a Complete Response Letter (CRL) on 26 January 2018, from the US Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Apulmiq as a treatment for non-cystic fibrosis bronchiectasis patients with chronic lung infection with Pseudomonas aeruginosa (P. aeruginosa). The CRL identified issues related to a manual re-review of patient-level pulmonary exacerbation (PE) data conducted by Aradigm after errors were discovered in the analyses performed by a contract research organization.

  • Associated Press

    Aradigm: 3Q Earnings Snapshot

    On a per-share basis, the Hayward, California-based company said it had a loss of 24 cents. The specialty pharmaceutical company posted revenue of $282,000 in the period. The company's shares closed at ...

  • Business Wire

    Aradigm Announces Third Quarter 2018 Financial Results

    Aradigm Corporation today announced financial results for the third quarter and nine months ended September 30, 2018.